Abstract:Allergic asthma is a stubborn chronic inflammatory disease, and is considered a co-result of various immune cells, especially mast cells, eosinophils and T lymphocytes. At present, the treatment methods of allergic asthma are limited and the side effects are obvious. Traditional Chinese medicine has been used to treat diseases for thousands of years in China. One such example is the treatment of allergic asthma, which take the characteristics of less adverse reactions and obvious curative effect. Tuo-Min-Ding-Chuan Decoction (TMDCD) is a traditional Chinese medicine compound for the treatment of allergic asthma optimized from Ma-Xing-Gan-Shi Decoction (MXGSD), which was put forward in Treatise on Febrile Diseases by Zhang Zhongjing in the Eastern Han Dynasty. The compound shows a significant clinical effect, but the mechanism of its influence on the immune system is still unclear. The purpose of this study was to observe whether TMDCD could alleviate the symptoms of ovalbumin (OVA) challenged allergic asthma mice, and to explore its immune regulatory mechanism, especially on mast cell (MC) degranulation. The results showed TMDCD could not only reduce the airway hyperresponsiveness (AHR), inflammatory cell infiltration and mucus secretion in the lung tissue of OVA challenged mice, but also decrease the levels of total IgE, OVA-specific IgE, histamine and LTC4 in serum. We found that TMDCD can downregulate the expression of Fractalkine, Tryptase ε, IL-25, CCL19, MCP-1, OX40L, Axl, CCL22, CD30, G-CSF, E-selectin, OPN, CCL5, P-selectin, Gas6, TSLP in OVA challenged mice serum by using mouse cytokines antibody array. It has been reported in some literatures that these differentially expressed proteins are related to the occurrence of allergic asthma, such as tryptase ε, MCP-1, CCL5, etc. can be released by MC. And the results of in vitro experiments showed that TMDCD inhibited the degranulation of RBL-2H3 cells stimulated by DNP-IgE/BSA. Taken together, we made the conclusion that TMDCD could reduce the infiltration of inflammatory cells in lung tissue and alleviate airway remodeling in mice with allergic asthma, showed the effects of anti-inflammatory and antiasthmatic. TMDCD could also reduce the levels of IgE, histamine, LTC4, Tryptase ε, and other MC related proteins in the serum of allergic asthma mice, and the in vitro experiments showed that TMDCD could inhibit IgE mediated degranulation and histamine release of RBL-2H3 cells, proved its anti allergic effect.

Novel Therapy for Allergy Through Immunomodulation by CD40-silenced Dendritic Cells

Potential Therapy of Fc-Antigen Combination-Encoding Dna Vaccination in Mouse Allergic Airway Inflammation

Induction of Adaptive T Regulatory Cells That Suppress the Allergic Response by Coimmunization of DNA and Protein Vaccines.

Inhibition of Mice Airway Allergic Inflammation by Inoculation of Tolerogenic Dendritic Cells

Silencing of CD86 in dendritic cells by small interfering RNA regulates cytokine production in T cells from patients with allergic rhinitis in vitro.

Co-delivery of allergen epitope fragments and R848 inhibits food allergy by inducing tolerogenic dendritic cells and regulatory T cells

The roles of thymic stromal lymphopoietin receptor and its antibody in airway inflammatory response in asthmatic mice

Lipopolysaccharide-Activated Bone Marrow-Derived Dendritic Cells Suppress Allergic Airway Inflammation by Ameliorating the Immune Microenvironment

Induction of Immune Tolerance in Asthmatic Mice by Vaccination with DNA Encoding an Allergen-Cytotoxic T Lymphocyte-Associated Antigen 4 Combination.

Microrna-106b Regulates Pro-Allergic Properties of Dendritic Cells and Th2 Polarisation by Targeting Early Growth Response-2 in Vitro

CD40 signaling augments IL-10 expression and the tolerogenicity of IL-10-induced regulatory dendritic cells

Tuo-Min-Ding-Chuan Decoction Alleviate Ovalbumin-Induced Allergic Asthma by Inhibiting Mast Cell Degranulation and Down-Regulating the Differential Expression Proteins

In Vivo Intranasal Anti-Cd23 Treatment Inhibits Allergic Responses in a Murine Model of Allergic Rhinitis.

Dendritic Cell Vaccine Design: Strategies for Eliciting Peripheral Tolerance as Therapy of Autoimmune Diseases

New insights into allergic rhinitis treatment: MSC nanovesicles targeting dendritic cells

Dendritic Cells Modified with Der P1 Antigen As a Therapeutic Potential for Allergic Rhinitis in a Murine Model Via Regulatory Effects on IL-4, IL-10 and IL-13

Tfh Exosomes Derived from Allergic Rhinitis Promote DC Maturation Through miR-142-5p/CDK5/STAT3 Pathway

Derp1-modified dendritic cells attenuate allergic inflammation by regulating the development of T helper type1(Th1)/Th2 cells and regulatory T cells in a murine model of allergic rhinitis

Small Interfering RNA Targeting T-cell Ig Mucin-3 Decreases Allergic Airway Inflammation and Hyperresponsiveness

In vitro-induced Foxp3+ CD8+ regulatory T cells suppress allergic IgE response in the gut

Co-delivery of Vitamin D3 and Lkb1 Sirna by Cationic Lipid-Assisted PEG-PLGA Nanoparticles to Effectively Remodel the Immune System in Vivo.